Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Leases (2020 - 2025)

Historic Operating Leases for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $22.5 million.

  • Foghorn Therapeutics' Operating Leases fell 2564.69% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2564.69%. This contributed to the annual value of $28.1 million for FY2024, which is 3773.66% down from last year.
  • Foghorn Therapeutics' Operating Leases amounted to $22.5 million in Q3 2025, which was down 2564.69% from $23.7 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Operating Leases high stood at $62.3 million for Q1 2021, and its period low was $22.5 million during Q3 2025.
  • For the 5-year period, Foghorn Therapeutics' Operating Leases averaged around $42.1 million, with its median value being $43.5 million (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 697.91% in 2021, then plummeted by 3773.66% in 2024.
  • Foghorn Therapeutics' Operating Leases (Quarter) stood at $58.3 million in 2021, then fell by 11.7% to $51.5 million in 2022, then decreased by 12.49% to $45.1 million in 2023, then plummeted by 37.74% to $28.1 million in 2024, then dropped by 19.72% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q3 2025, $23.7 million for Q2 2025, and $25.7 million during Q1 2025.